Our findings demonstrate that bufalin can significantly inhibit colorectal cancer stemness and tumorigenesis, which is accompanied by its activity against EMT markers (Slug, ZEB1, N-Cadherin) and functional stem cell markers (CD44, CD133, LGR5, ALDH, and pluripotency factors). This evidence concerns the gene SNAI2 and colorectal cancer.